Congestive heart failure biventricular pacing or cardiac resynchronization therapy: Difference between revisions

Jump to navigation Jump to search
 
(8 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{Congestive heart failure}}
#redirect:[[Cardiac resynchronization therapy]]
 
'''Editor(s)-In-Chief:''' James Chang, M.D., Cardiovascular Division Beth Israel Deaconess Medical Center, Boston MA, Harvard Medical School [mailto:jchang@caregroup.org] and [[User:C Michael Gibson|C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org], Cardiovascular Division Beth Israel Deaconess Medical Center, Boston MA, Harvard Medical School
 
==Overview==
* Cardiac resynchronization therapy should only be undertaken if the blood pressure is low and if the heart failure medicines have been optimized
* CRT is indicated for symptomatic patients with NYHA III-IV heart failure and wide QRS complex (>120ms) who are him normal sinus rhythm.
* 70% of patients receiving synchronous ventricular contraction report significant symptomatic improvements.
 
==Indications for Cardiac Resynchronization Therapy==
 
1. The [[left ventricular ejection fraction]] ([[LVEF]]) is ≤ 35%
 
'''''and'''''
 
2. There is evidence of [[left bundle branch block]] ([[LBBB]]) or QRS ≥ 120 msec
 
'''''and'''''
 
3. Left ventricular end-diastolic diamter (LVEDD) ≥ 5.5 cms
 
===Background===
*[[Cardiac resynchronization therapy]] ([[CRT]]) is recommended for all patients with [[LVEF]] ≤ 35%, dilated LV (LVEDD > 5.5 cm), [[left bundle branch block]] (QRS duration > 120 msec), and [[sinus rhythm]]. CRT improves functional status and decreases mortality in the majority of these patients.
 
*In the REVERSE and MADIT-CRT trials patients with [[NYHA classification|NYHA I or II]] had decreased heart failure events and increased reverse remodeling of the left ventricle. This is not yet an ''AHA guideline'' but should be considered in this group of patients based on the available evidence.
 
==ACC / AHA Guidelines - Recommendations for Cardiac Resynchronization Therapy in Patients with Severe Systolic Heart Failure (DO NOT EDIT)<ref name="pmid18483207">{{cite journal |author=Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW |title=ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons |journal=[[Circulation]] |volume=117 |issue=21 |pages=e350–408 |year=2008 |month=May |pmid=18483207 |doi=10.1161/CIRCUALTIONAHA.108.189742 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=18483207 |issn= |accessdate=2011-01-15}}</ref>==
{{cquote|
====[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]====
 
'''1.'''  For patients who have LVEF less than or equal to 35%, a QRS duration greater than or equal to 0.12 seconds, and sinus rhythm, CRT with or without an ICD is indicated for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms with optimal recommended medical therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
 
====[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]====
 
'''1.''' For patients who have LVEF less than or equal to 35%, a QRS duration greater than or equal to 0.12 seconds, and AF, CRT with or without an ICD is reasonable for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms on optimal recommended medical therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
 
'''2.''' For patients with LVEF less than or equal to 35% with NYHA functional Class III or ambulatory Class IV symptoms who are receiving optimal recommended medical therapy and who have frequent dependence on ventricular pacing, CRT is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])
 
====[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]====
 
'''1.''' For patients with LVEF less than or equal to 35% with NYHA functional Class I or II symptoms who are receiving optimal recommended medical therapy and who are undergoing implantation of a permanent pacemaker and/or ICD with anticipated frequent ventricular pacing, CRT may be considered. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])}}
 
==References==
{{Reflist|2}}
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
 
[[Category:Disease]]
[[Category:Cardiology]]
[[Category:Emergency medicine]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]

Latest revision as of 01:25, 8 April 2012